In conclusion, our results demonstrate that HIF1 is a major factor controlling the aggressive and chemotherapy-resistant phenotype of Rab25 expressing ovarian cancers and indicate that targeting HIF-1 activity might be effective either alone or in combination with standard chemotherapy for aggressive metastatic ovarian cancer. This evidence concerns the gene HIF1A and ovarian carcinoma.